Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents (A61P1/14)

A   Human necessities(312083)
A61P1/14                     Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents(106)
Hetero-aromatic methylic derivative of cyclic amine // 2639869
FIELD: chemistry.SUBSTANCE: invention relates to a compound represented by the formula (IA), where X1 and X2 are the same or different and are a nitrogen atom or a CH group; Y is any structure from the following group of formulas (a); n is 1 or 2; R1 is a hydrogen atom, a halogen atom or a C1-6 alkyl group; R2 is a triazolyl group or a pyrimidinyl group; R3 is a hydrogen atom or a halogen atom; and R4 is a hydrogen atom or a C1-6 an alkyl group; or a pharmaceutically acceptable salt thereof. The invention also relates to a compound represented by the formula (I), where X1 and X2 are the same or different and are a nitrogen atom or a CH group; any one of Y1 and Y2 is a nitrogen atom, and the other is CH; n is 1 or 2; R1 is a hydrogen atom, a halogen atom or a C1-6 alkyl group;R2 is a triazolyl group or a pyrimidinyl group; R3 is a hydrogen atom or a halogen atom; and R4 is a hydrogen atom or a C1-6 alkyl group; or a pharmaceutically acceptable salt thereof. The compounds of the invention are intended for the production of a pharmaceutical composition having antagonistic activity against OX1 and OX2 orexin receptors.EFFECT: hetero-aromatic methyl derivative of cyclic amine, which has antagonistic activity against OX1 and OX2 orexin receptors.9 cl, 6 tbl, 85 ex
ethod for intestinal flora stimulation // 2639490
FIELD: medicine.SUBSTANCE: at that, this composition is adapted for enteral administration to infants. The composition comprises at least one microorganism and at least non-digestible galactooligosaccharides, wherein the said microorganism is at least one species of Bifidobacteria selected from the group consisting of Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium catenulatum, Bifidobacterium adolescentis and Bifidobacterium longum.EFFECT: invention allows to stimulate healthy development of intestinal flora in these infants.9 cl, 2 tbl, 6 ex
ethod for correction of psychosomatic diseases in patients with irritated bowel syndrome // 2637628
FIELD: medicine.SUBSTANCE: for correction of anxiety and depression in patients with irritable bowel syndrome 10 mg of "Cipralex" 1 time per day for three months, or 25 mg of "Atarax" 1 pill 2 times a day for two months and "Enterosan" 1 capsule 3 times a day 15-20 minutes before meals are prescribed for two months alongside with a diet.EFFECT: method allows to reduce regression times of pain and dyspeptic syndromes.2 ex
Dietary fiber for application while treating adverse effects of nutrition or medicinal agent on gastrointestinal tract // 2637133
FIELD: food industry.SUBSTANCE: mixture of dietary fibers for a food product or for a pharmaceutical composition is proposed, comprising a medicinal agent having inhibiting effect on serotonin reuptake, inhibiting effect on the oxidation of monoamines, or an opiate, a cereal fiber other than a resistant starch and a gum, and at least a fiber from the following two groups: a gum; fibers from tubers or roots; fibers from beans or kidney beans, and fibers from plant leaves and fruits. A method of prophylactic or therapeutic treatment of a person in need thereof is proposed, wherein the treatment comprises applying an effective amount of dietary fibers in combination with a pharmaceutical composition or nutrition, thereby reducing the saturating effect of the pharmaceutical composition or the nutrition.EFFECT: inhibiting or reducing the saturation effect of clinical nutrition or a medicinal agent.36 cl, 5 tbl, 11 ex

ethods and compositions to improve intestinal microbiota population and their implementation // 2631595
FIELD: medicine.SUBSTANCE: use of berberine is described, which allows to selectively increase the first population of the intestinal microbiota, while reducing the second population of the intestinal microbiota in the subject. The first intestinal microbiota population includes a short-chain fatty acid producing bacterium (SCFA) and the second intestinal microbiota population includes an endotoxin-producing bacterium.EFFECT: group of inventions allows to improve the intestinal microbiota structure.18 cl, 6 dwg, 1 tbl, 1 ex
Polybacterial drug with advantages for health: with antioxidant effect, decreased cholesterol concentration, anti-inflammatory and immuno-modulating effect, and release of bioactive peptides inhibiting angiotensin-converting enzyme // 2627651
FIELD: biotechnology.SUBSTANCE: group of inventions refers to polybacterial probiotic drug including new strains of lactic acid bacteria Lactobacillus gasseri 7/12 NBIMCC No. 8720, Lactobacillus plantarum F12 NBIMCC No. 8722 and Lactobacillus helveticus A1, NBIMCC No. 8721, which has anti-inflammatory immunomodulatory, hypocholesterolemic, antioxidant and antihypertensive activity. The group of inventions also refers to the use of drug as a probiotic agent, as well as an agent which has anti-inflammatory immunomodulatory, hypocholesterolemic, antioxidant and antihypertensive activity.EFFECT: food additives, food and functional products, pharmaceutical preparations that include this drug, have a beneficial effect on the health of people and animals.9 cl, 8 dwg, 15 tbl

Composition for use during angiogenesis augmentation in intestine, nutrient absorption and tolerance to enteral nutrition, and/or during prevention and/or treatment of inflammatory intestine diseases, and/or during recovery from intestine injury and surgical intervention // 2624233
FIELD: pharmacology.SUBSTANCE: composition comprising at least one longchain polyunsaturated fatty acid (LC-PUFA), at least one probiotic and a mixture of oligosaccharides comprising at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide for angiogenesis augmentation in intestine and nutrient absorption, tolerance to enteral nutrition of suckling children or growing infants; its use as a synthetic nutrient agent for the same purpose; composition of the same formulation used during prevention and/or treatment of inflammatory intestine diseases, representing necrotizing enterocolitis, and/or during recovery from injury and/or surgical intervention in the intestine area of suckling children or growing infants, and its use as a synthetic nutrient agent for the same purpose are proposed.EFFECT: angiogenesis augmentation in intestine, which enables to reduce the risk of necrotizing enterocolitis and facilitates recovery from injury or surgical intervention in intestine of suckling children or growing infants.26 cl, 4 dwg, 4 tbl
edication for treating calves in case of acute intestinal diseases // 2611342
FIELD: medicine.SUBSTANCE: invention relates to field of veterinary and is intended for treatment of calves in case of diarrhoea of infectious and alimentary-functional nature. Medication contains sodium chloride, hydrocarbonate, sodium chloride, glucose, iodine-bismuth complexonate (IBC) with the following component ratio, g/l of solution: sodium chloride - 3.5; sodium hydrocarbonate - 2.5; potassium chloride - 1.5; glucose - 20.0; IBC - 0.5.EFFECT: application of the invention ensures increase of effectiveness and safety of treatment in case of acute intestinal diseases of calves.2 dwg, 5 tbl, 2 ex
Cynara scolymus for treating dyslipidemia // 2608459
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, namely to extract of leaves of different types of Cynara and pharmaceutical composition, containing as active ingredient, leaf extract of Cynara types, which can be used in treating hyperglycemia, hypercholesterolemia, hypertension and hepatic steatosis.EFFECT: above extract and composition are characterized by considerable increase of HDL cholesterol level.9 cl, 3 tbl
ethod of treating intestinal dysbacteriosis // 2602696
FIELD: medicine.SUBSTANCE: invention relates to medicine and is aimed at treating intestinal infections and dysbacteriosis. Treatment is carried out in three stages: first stage involves introduction of probiotics of bacteria of genus Bacillus to suppress pathogenic microflora and recovery of intestinal mucosa, second stage involves successive introduction of suspension auto-strains of bifido- and(or) lactic acid bacilli, and third stage consists in additional introduction of probiotics of bacteria of genus Bacillus for 7-10 days for stimulating surival of bifido- and(or) lactic acid bacilli.EFFECT: method provides higher treatment effectiveness.1 cl, 3 ex

Diaminopyrimidine derivatives and methods for production thereof // 2587981
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a novel compound of diaminopirimidine formula 1 or its pharmaceutically acceptable salts possessing the properties of 5-HT4 receptors agonist. In formula 1 (Formula 1)R1 denotes a phenyl group substituted with one or more substitutes selected from a group consisting of hydroxy, amino, halogen, cyano, nitro, C1-2alkyl (where C1-2alkyl optionally substituted with halogen), C1-5alkoxy,C1-5alkylthio, C1-5alkoxycarbonyl and aminokarbonil, or heteroaryl group selected from a group consisting of furanyl, pyrrolyl, tiofenil, hinolinil, hromenonil, indolil, benzimidazole-4-yl, benzimidazole-5-yl, benzimidazole-6-yl, benzimidazole-7-yl and indazolil, herewith the heteroaryl group can be optionally substituted with one or more substitutes selected from a group consisting of C1-5alkyl (where C1-5alkyl optionally substituted with halogen) and C1-5alkoxy, R2 denotes a nitrogen-containing cyclic group selected from a group consisting of the following formulae from A to D (where * symbol in A-D formulae denotes the position of this group attachment to a compound of formula (1))R3 denotes C1-5alkyl group, optionally substituted by phenyl, R4 denotes hydrogen, C1-5alkyl group optionally substituted with a substitute selected from a group consisting of hydroxy, C1-5alkylamino, pyrrolidinyl and hydroxy-C-1-5alkylamino; C1-5alkoxycarbonyl group or amin-carbonyl group, R5 denotes hydrogen, hydroxyl group; C1-5alkoxy group; C1-5alkyl group, optionally substituted with a substitute selected from a group consisting of amino and C1-5alkoksikarbonilamino; or group selected from a group consisting of the following formulae of E to I (where * symbol in E-I formulae is the position of this group attachment to one of the of A-D formula compounds),R6 means hydrogen, hydroxyl group or C1-5alkyl group optionally substituted with hydroxy, X denotes -CH(R7)-, -C(=O)-, -N(R8)- or -O-, R7 means hydrogen; hydroxyl group; amino-carbonyl group; phenyl group or C1-5alkyl group optionally substituted with hydroxy, R4 and R5, R5 and R6, R4 and R6 or R5 and R7 may be interconnected while forming 5- or 6-element ring; the said ring may be carbocyclic or additionally contain an oxygen atom as a heteroatom, R8 denotes hydrogen or C1-5alkyl group. Values of R9-R12 radicals are given in the patent claim.EFFECT: invention relates to the use of formula 1 or its pharmaceutically acceptable salt for preparing a drug in order to prevent or treat gastrointestinal motility dysfunction; Gastrointestinal motor dysfunction is gastroesophageal reflux disease (GERD), a lock (constipation), an irritable bowel syndrome (IBS), dyspepsia, postoperative intestinal obstruction, prolonged gastric emptying, gastroparesis, intestinal pseudo-obstruction, content transit deceleration over the colon induced by medicines or diabetic gastroparesis.8 cl, 38 tbl, 355 ex

Diaminopyrimidine derivatives and methods for production thereof // 2587493
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a novel diaminopyrimidine derivative formula 1 or pharmaceutically acceptable salts thereof possessing properties of agonist of 5-HT4 receptors. In formula 1 (Formula 1)R1 denotes a phenyl group substituted with one or more substitutes selected from a group consisting of hydroxy, amino, halogen, cyano, nitro, C1-5alkyl (where C1-5alkyl is optionally substituted with halogen), C1-5alkoxy, C1-5alkylthio, C1-5alkoxycarbonyl, aminosulphonyl and benzyloxycarbonylamino; or heteroaryl group selected from a group comprising pyridinyl, quinolinyl, chromenonyl, indolyl, indolinyl and benzimidazolyl, wherein heteroaryl group can be optionally substituted with one or more substitutes selected from a group consisting of C1-5alkyl (where C1-5alkyl is optionally substituted with halogen) and acetyl, R2 denotes hydrogen; C1-5alkyl group, optionally substituted with a substitute selected from a group consisting of hydroxy, C1-5alkoxy, benzylamino (where benzylamino is optionally substituted by halogen), phenylamino, C1-5alkylamino, C3-6cycloalkylamino and hydroxy-C1-5alkylamino; C1-5alkoxycarbonyl group or formyl group, R3 denotes hydrogen, hydroxyl group; C1-5alkyl group, optionally substituted with a substitute selected from a group consisting of C1-5alkoxycarbonylamino and di-C1-5alkylamino, or group selected from a group consisting of following formulae A, B, D and E (where symbol * in formulae A, B, D and E denotes position of attachment of said group of compounds of formula 1),R4 denotes hydrogen, R5 denotes C1-5alkyl group, optionally substituted phenyl or C2-6alkenyl group, optionally substituted phenyl or C3-6cycloalkyl, R6 denotes C1-10alkyl group, optionally substituted with a substitute selected from a group consisting of hydroxy, halogen, C1-5alkoxy, amino, C1-5alkoxycarbonylamino, benzyloxycarbonylamino, di-C1-5alkylamino, C1-5alkoxy-C1-5alkyloxy, phenoxy, benzyloxy, phenyl (where phenyl is optionally substituted with one or more substitutes selected from a group consisting of halogen, amino and C1-5alkoxy), thiophenyl, pyridinyl, piperidinyl, piperazinyl (where piperazinyl is optionally substituted with benzyl) and acetyl; C3-6cycloalkyl group; piperidinyl group; C1-10alkenyl group, optionally substituted phenyl; trifluoromethyl group, trifluoroethyl group or a phenyl group optionally substituted with halogen, R7 denotes hydrogen, R8 and R9 each independently denote hydrogen; C1-10alkyl group, optionally substituted with substitute selected from a group consisting of amino, C1-5alkoxycarbonylamino, hydroxy, C1-5alkylthio, C3-10cycloalkyl, phenyl (where phenyl is optionally substituted with one or more substitutes selected from a group consisting of hydroxy, C1-5alkyl, mono-or di-C1-5alkylamino, trifluoromethyl, halogen, C1-5alkoxy C1-5alkylcarbonyloxy), thiophenyl, pyrrolyl, furanyl (where furanyl is optionally substituted with mono-or di-C1-5alkyl), pyridinyl and benzyloxy; piperidinyl group, optionally substituted benzyl, benzoyl, C1-5alkyl or C1-5alkylcarbonyl; azetidinyl group, optionally substituted C1-5alkoxycarbonyl; C1-5alkylsulphonyl group or C3-10cycloalkyl group.EFFECT: invention relates to use of formula 1 or its pharmaceutically acceptable salt for preparing a drug for preventing or treating gastrointestinal motility dysfunction; gastrointestinal motor dysfunction is gastroesophageal reflux disease (GERD), lock (constipation), irritable bowel syndrome (IBS), dyspepsia, postoperative intestinal obstruction, prolonged gastric emptying, gastroparesis, intestinal pseudo-obstruction,drug-induced delayed transit content over colon or diabetic gastroparesis.9 cl, 54 tbl, 495 ex
Therapeutic agent for gastrointestinal disease // 2577302
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to pharmaceutics and medicine and concerns a therapeutic or preventive agent stimulating tissue cell migration of gastrointestinal mucosa, containing a peptide with the amino acid sequence Ser-Ser-Ser-Arg, or its pharmaceutically acceptable salt. Besides, the peptide with the amino acid sequence Ser-Ser-Ser-Arg or its pharmaceutically acceptable salt, and the peptide with the amino acid sequence Phe-Gly-Leu-Met-NH2 or its pharmaceutically acceptable salt are introduced in a combination. The declared agents are used in a method of treating pathology of gastrointestinal mucosa.EFFECT: group of inventions provides synergetic action when is used in a combination, and can substantially induce wound healing in gastrointestinal mucosa.14 cl, 1 tbl

ethod of treating patients with intestinal disbacteriosis // 2571495
FIELD: medicine.SUBSTANCE: hepatotropic preparation Hepaguard Active is administered in a dose of 1 capsule 3 times a day at mealtimes for 28-30 days.EFFECT: method enables recovering and maintaining the optimum health of intestinal microbiocenosis by ensuring a possibility to have an effect on its various links.3 tbl, 4 ex
Compositions of pancreatic enzymes and method of treating pancreatitis and pancreas insufficiency // 2570376
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to medicine and describes a composition of digestive enzymes which contains granules covered with an enterosoluble coating, which contain a digestive enzyme, and digestive enzyme-containing granules, which are not covered with a coating, where the granules covered with the enterosoluble coating, which contain the digestive enzyme, contain a core and the enterosoluble coating, located on the core, where the core contains a therapeutically effective quantity of lipase, and the enterosoluble coating contains an enterosoluble polymer; and the digestive enzyme-containing granules, which are not covered with a coating, contain a therapeutically effective quantity of protease and in fact do not contain the enterosoluble polymer coating; where the lipase activity of the coating-covered granules is in the range from approximately 1000 USP units to approximately 10000 USP units, and protease activity in the granules which are not covered with the coating is in the range from approximately 65000 USP units to approximately 34000 USP units. Also methods of treating pain in case of pancreatitis and pancreas insufficiency, as well as a method for the treatment of exocrine insufficiency of the pancreas are described.EFFECT: group of inventions makes it possible to achieve an effective and safe clinical result in a low dose.16 cl, 20 tbl, 10 ex

ethod of prevention post-infectious irritable bowel syndrome // 2553372
FIELD: medicine.SUBSTANCE: invention is intended for prevention of post-infectious irritable bowel syndrome (PI-IBS). Peroral intake of autoprobiotic, representing individual lactic product, prepared on the basis of Enterococcus faecium strain, and containing 108 CFU in 1 ml of product. Inoculation of bacteria from patient's feces on selective nutritional medium is performed, with further culture growing in selective nutritional medium, identification and selection of colonies, typical for Enterococcus faecium, obtaining pure culture of Enterococcus faecium and specification of species and content of pathogenecity factors by method of polymerase chain reaction, selection of apatogenic clones of Enterococcus faecium, corresponding to standards of genetic safety and physiological functionality, which are used to prepare lactic starter culture. Autoprobiotic is introduced in dose not less than 100 ml/day, with course constituting not fewer than 10 days. Selected apathogenic clones of Enterococcus faecium are deposited in cryostorage at temperature not higher than -75°C with storage term not longer than 1 year. Enterococcus-agar is used as selective nutritional medium.EFFECT: method makes it possible to increase efficiency of prophylaxis of PI-IBS patients due to reduction of its development frequency.3 cl, 1 tbl, 1 ex

Prolonged release formulation containing octreotide and three linear polymers of poly(lactide-co-glycolic acid) // 2541104
FIELD: medicine, pharmaceutics.SUBSTANCE: claim describes prolonged release formulations containing an active ingredient presented by octreotide or its pharmaceutically acceptable salt and three various linear polymers of poly(lactide-co-glycolic acid) (PLGA). The first PLGA has the lactide:glycolic acid relation of 65:35; the second PLGA has the lactide:glycolic acid relation of 75:25; the third PLGA has the lactide:glycolic acid relation of 85:15. The octrotide composition containing three various linear polymers of PLGA is characterized by the plasma octreotide concentration of low variability over the period of time making more than three months.EFFECT: composition is applicable for the prolonged supporting therapy of the patients suffering acromegalia and for treating diarrhoea and congestions associated with malignant carcinoids and tumours producing vasoactive intestinal peptides (VIPoma-like tumours).18 cl, 4 tbl, 5 ex
ethod of treating and preventing gastrointestinal diseases in newborn calves // 2538651
FIELD: medicine.SUBSTANCE: invention refers to veterinary medicine and can be used for treating and preventing gastrointestinal diseases accompanied by diarrhoeas in newborn calves Substance of the method consists in adding the oral administration of a therapeutic mixture of antibacterial, antitoxic and rehydration agents with the intramuscular injections of immunofan in a single dose of 1 ml 2-3 times every second day.EFFECT: method provides increasing the therapeutic and preventive effectiveness in acute gastrointestinal diseases in newborn calves.2 tbl, 2 ex

acrocyclic alkylammonium derivatives of 6-methyluracil having anticholinesterase activity // 2534903
FIELD: chemistry.SUBSTANCE: invention relates to novel macrocyclic alkylammonium derivatives of 6-methyluracil of formula (1). The compounds have anticholinesterase activity and can be used for pharmacological correction of synaptic defects which cause Alzheimer's disease, myasthenia gravis and other forms of pathological muscle weakness. The compounds can be used when treating glaucoma, intestinal atony, alcoholism, schizophrenia, manic-depressive psychosis, traumatic brain injury, sleep disorders, etc. In formula (1) X=NO2, Y=(CH2)4 (1a); X=CN, Y=(CH2)4 (1b); X=NO2, Y=C6H4 (1c); X=CN, Y=C6H4 (1d).EFFECT: improved properties of compounds.2 cl, 2 tbl, 9 ex
ethod of treating patients with dyspepsia syndrome combined with overweight // 2528641
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to gastroenterology, and can be used for providing the higher clinical effectiveness in the patients suffering dyspepsia syndrome combined with overweight. The method involves measuring an anxiety level (HARS) and a depression level (HDRS) according to Hamilton rating scales, assessing nutritional status by bioimpedancemetry, a degree of manifestation of sleep disorders, measuring glucose, testing glucose tolerance, immunoreactive insulin, cholesterol, high-density lipoprotein (HDLP), triglyceride in venous blood. If the patient is observed to suffer dyslipidemia and impaired glucose tolerance or variations of immunoreactive insulin, the preparation Dibikor is administered in a dose of 500 mg a day for three months. The patient suffering dyslipidemia and both of the disorders stated above requires administering Dibikor 1000 mg a day for three months. If the patient suffers an overweight with a body weight index falling within the range of 27 to 29.9 standard units and an active cell mass (ACM) percentage of 45 to 55 per cent as shown by bioimpedancemetry, the preparation Dietressa is administered in a dose of 1 tablet 3-4 times a day for three to six months. If the patient suffers an overweight with a body weight index falling within the range of 27 to 29.9 standard units and an active cell mass (ACM) percentage of 45 to 55 per cent as shown by bioimpedancemetry, the preparation Dietressa is administered in a dose of 2 tablet 3-4 times a day for three to six months. If the patient suffers mild and moderate sleep disorders and shows an emotive type of eating behaviour combined with mild affective disorders, the anti-depressant Valdoxane in a single dose of 25 mg a day for the night for two weeks. The course of the disease is followed by the anxiety and depression levels two weeks after the beginning of the therapy, with the positive progression of the diseases, the 25mg dose of Valdoxane remains unchanged to the end of the therapeutic course for three to six months. If no progression is exhibited, the dose is to be increased to 50 mg a day, and the therapy is continued from four to eight months. If the patient suffers severe sleep disorders and shows an emotive type of eating behaviour combined with moderate affective disorders, the anti-depressant Valdoxane in a single dose of 50 mg a day for the night for two to three months.EFFECT: in each specific case, the method enables providing faster reduction of the clinical symptoms, including body fat weight reduction and active cell mass and water normalisation, normalising circadian rhythms of the vegetative balance, as well as prolonging the remission.3 tbl, 2 ex
Agent or stimulation of metabolic processes, prevention and treatment of gastrointestinal diseases in calves in early postnatal period // 2521369
FIELD: veterinary medicine.SUBSTANCE: agent or stimulation of metabolic processes, prevention and treatment of gastrointestinal diseases in calves in early postnatal period comprises succinic acid as the energy stimulant, beet molasses as carbohydrate component, methionine as the stimulant of the digestive system, iodinol as the anti-infective component, and water in the following ratio of components, based on 0.5 litre: succinic acid 5.0 g; beet molasses 150.0 ml; methionine 2.0 g; iodinol 30-50 ml; water - the rest.EFFECT: improvement of agent efficiency.5 tbl, 2 ex

ethod of treating low-body-weight premature newborns // 2514346
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to paediatrics and neonatology, and can be used for treating small premature infants at the hospital stage of developmental care. A therapeutic complex comprises administering a probiotic preparation into the newborns. The preparation is presented with a liquid probiotic containing E.faecium L3 109 CFU in 1 ml. If the enteral nutrition volume of the newborn is 5 ml or more, this preparation is orally administered in a dose of 0.5 ml 3 times a day for 14 days.EFFECT: method is effective in children with a very low body weight, promotes normalising the intestinal microflora and reducing a rate of manifestations of infectious complications.2 ex, 3 dwg, 3 tbl

Crystalline forms of 3-carboxypropyl-aminotetralin compound // 2512390
FIELD: chemistry.SUBSTANCE: invention provides crystalline solid form of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalin-2-ylamino)-2-cyclohexylmethyl-butyric acid or crystalline hydrochloride of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalin-2-ylamino)-2-cyclohexylmethyl-butyric acid. Invention relates to pharmaceutical composition, possessing antagonistic activity with respect to mu-opioid receptor, which contains therapeutically effective quality of crystalline solid form.EFFECT: invention provides methods of applying claimed crystalline solid forms in treatment of diseases associated with activity of mu-opioid receptors and methods of obtaining claimed crystalline solid forms.27 cl, 9 dwg, 17 ex
Preparation for prevention of diarrhoea in newborn calves // 2504386
FIELD: medicine.SUBSTANCE: invention refers to veterinary science. A preparation for the prevention of diarrhoeas in newborn calves containing acid hydrolysate of animal blood, lactic, benzoic, succinic acids, additionally contains acetic acid, in the following ratio, wt %: acetic acid 0.4-0.5, lactic acid 0.05-0.06, benzoic acid 0.04-0.05, succinic acid 0.02-0.03, acid hydrolysate of animal blood - the rest.EFFECT: invention provides a lower probability of diarrhoeas in the newborn calves and reducing a mortality rate.3 tbl, 6 ex

ethod for relieving abdominal murmur by introducing bacteria of genus bifidobacterium // 2492869
FIELD: medicine.SUBSTANCE: invention refers to medicine and may be used for relieving abdominal murmur. That is ensured by the oral administration of the bacteria Bifidobacterium animalis in dose 1×109 CFU a day. The bacteria are administered every day, for at least 15 days.EFFECT: method provides relieving abdominal murmur in a healthy individual that is ensured by the developed dose schedule and specific rate of administration of the above prebiotic.10 cl, 1 ex

Composition of probitic bacteria with prebiotic, and using it in preventing and/or treating respiratory pathologies and/or infections, and for improving intestinal function // 2491081
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics, namely to a composition for preventing and/or treating respiratory pathologies and/or infections and for improving intestinal functions. Using a symbiotic composition for preparing a drug preparation for preventing and/or treating the respiratory pathologies and/or infections. The symbiotic composition containing an active ingredient presented by a) a mixture containing the following bacterial strains: Lactobacillus plantarum LMG P-21020; Lactobacillus plantarum LMG P-21021; Lactobacillus rhamnosus DSM 16605; Lactobacillus rhamnosus DSM 19739; Bifidobacterium lactis LMG P-21384 and b) a prebiotic ingredient containing at least one scFOS (short-chain fructooligosaccharide) or GOS (galactooligosaccharide).EFFECT: using the declared method enables more effectively preventing and/or treating the respiratory pathologies with simultaneously improving and/or controlling the intestinal functions.11 cl, 2 tbl, 2 ex
ethod of treating secondary lactase deficiency // 2477633
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly gastroenterology, and may be applied in treating secondary lactase deficiency. For this purpose, with underlying diet and drug-induced therapy, bifiform 1 tablet 2-3 times a day and No-spa 1-2 tablets 3 times a day are additionally administered. The therapeutic course makes 14 days.EFFECT: method enables higher clinical effectiveness in secondary lactase deficiency.3 ex

Use of ghrelin splicing version for treating cachexia and/or anorexia, and/or anorexia-cachexia, and/or eating disorder, and/or lipodystrophy, and/or muscle atrophy, and/or appetite stimulation // 2470940
FIELD: medicine.SUBSTANCE: invention provides using a prepared compound of a ghrelin splicing version for preparing an effective drug preparation activating body weight and food intake gain and/or stimulating growth hormone release, as well as for treating or preventing cachexia, lipodystrophy and muscle atrophy.EFFECT: higher clinical effectiveness.6 cl, 6 dwg, 13 ex

Probiotic in pre- and/or postoperative period // 2470652
FIELD: medicine.SUBSTANCE: what is presented is the use of the strain Lactobacillus johnsonii in preparing a probiotic composition for prevention of postoperative abdominal and pelvic infections caused by pelvic liquid accumulation, anastomosis leakage, or caused by bacterial translocation.EFFECT: colonic L Johnsonii Lai colonisation in the patients underwent colectomy for colorectal adenocarcinoma.11 cl, 1 dwg, 1 tbl, 2 ex
Application of indigestible saccharides for better adaptation of newborns // 2462252
FIELD: medicine.SUBSTANCE: there are offered: application of a water-soluble indigestible saccharide for preparing a composition wherein the composition is introduced in a pregnant woman for improving the developing intestinal microflora of an expected newborn; reinforcing the immune system and/or preventing the diseases associated with the immune system of the expected newborn; or reinforcing the immune system of the foetus (versions). What is also presented is the application of the water-soluble indigestible saccharide wherein the saccharide is a galactose-containing saccharide containing at least 50% of galactose units of the total amount of monosaccharide units found in the saccharide for preparing the composition for reinforcing the immune system of the pregnant woman; improving the vaginal flora of the pregnant woman wherein the composition is introduced in the pregnant woman.EFFECT: increased percentage of bifidus bacteria and lactic acid bacilli in the intestinal flora of pregnant women, intestinal colonisation of the newborn by lactic acid bacilli and reinforcement of the immune system.11 cl, 2 ex
ethod of treating dyspepsia in calves // 2461387
FIELD: medicine.SUBSTANCE: invention relates to veterinary science. A method includes the administration of a medicinal agent. The medicinal agent is presented by 0.25% alcohol solution of Chlorophyllipt 3 ml in normal saline 57 ml which is introduced intravenously twice a day for 2-3 days in dose of 60 ml per a calve if observing simple dyspepsia and four times if observing toxic dyspepsia. It is combined with the oral introduction of 1% alcohol solution of Chlorophyllipt 10 ml at 900 ml in normal saline prescribed twice a day in dose 1000 ml in both forms of dyspepsia.EFFECT: method provides higher therapeutic effectiveness, reduces length of treatment, has no side action on calve bodies, eliminates recurrences.1 ex
Bifidobacterium longum strain used for preparing bifidus products // 2460777
FIELD: medicine.SUBSTANCE: strain Bifidobacterium longum B-NH is recovered from a healthy infant, actively propagates in a nutrient medium with accumulation of an production biomass in a short 12-18-hour period of cultivation time of the high bifidus bacteria concentration, is able to sour milk. The Bifidobacterium longum B-NH strain exhibits acid-forming activity, pathogen and opportunistic pathogen antagonist activity. It makes it possible to use the strain Bifidobacterium longum B-NH as an ingredient of bifidus products - bacterial preparations, biologically active food additives, fermented and non-fermented foodstuff, toiletry and care preparations enabling normalised human body microbiocenosis, including gastrointestinal and urogenital tracts, skin and mucous membranes, and extends the range of products for correction of human microflora. The strain Bifidobacterium longum B-NH is deposited in Russian National Collection of Industrial Microorganisms, No. VKPM Ac-1876.EFFECT: invention provides higher activity of bifidus products.2 tbl, 5 ex

ethod of complex treatment of dysbacteriosis at resort stage // 2460508
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to balneology, physiotherapy. First, individual sensitivity of patient to radon procedures is estimated. For this purpose, arterial pressure and heart rate are measured on empty stomach. After that, patient takes bath with mineral water from thermal radon springs with natural water temperature about 38°C (radon water). Patient rests for 30 minutes. After that, patient's arterial pressure and heart rate are re-measured. If heart rate does not change or changes by ±10 beats/min, and systolic and/or diastolic arterial pressure changes by ±10 mm Hg, I type of response is determined in patient. If heart rate changes by ±20 beats/min, and systolic and/or diastolic arterial pressure changes by ±15 mm Hg, II type of response is determined in patient. If heart rate changes by ±30 beats/min, and systolic and/or diastolic arterial pressure changes by ±20 mm Hg, III type of response is determined. In case of I type of response bath is taken according to the scheme: first procedure - 5 minutes, second - 8 minutes, third - 10 minutes, after that all procedures last 15 minutes. In case of II type of response bath is taken according to the scheme: first procedure - 5 minutes, second - 8 minutes, third - 10 minutes, after that all procedures last 12 minutes. In case of III type of response bath is taken according to the scheme: first procedure - 3 minutes, second - 5 minutes, third - 8 minutes, after that all procedures last 10 minutes. Course includes 10-15 baths. Bath with radon water is taken two days running, which are followed by one-day break. Treatment is performed at the background of diet No 4 b. In the first part of the day, two hours after breakfast, patient drinks 200 ml of radon water in swallows at a measured pace. On one of the days with baths, going one after another, microclysters with pantohematogen are performed. Detensor-therapy is carried out. In the second part of the day, two hours after dinner, patient drinks 200 ml of radon water in swallows at a measured pace. After that, patient takes bath with radon water. Then, procedure in accordance with programme of resonance-acoustic fluctuations (PRAF) is performed. On the days without baths in the first part of the day intestinal lavage is performed and in the second part of the day - thalassotherapy of face and body.EFFECT: method ensures increased efficiency of treatment of patients with dysbacteriosis at resort stage due to ensuring elimination of pathogenic and opportunistic microorganisms, and increase of immunologic reactivity of organism.4 cl, 2 tbl
Oral composition containing nonpathogenic microorganisms showing ability to normalise intestinal microflora (versions) // 2453320
FIELD: medicine.SUBSTANCE: group of inventions refers to pharmaceutical industry and medicine and is applicable for producing and using medical immunobiological preparations containing nonpathogenic microorganisms. The compositions (versions) represent a powder containing substances containing nonpathogenic microorganisms dried up in a culture medium specified in a number: Bifidobacterium bacteria and/or Lactobacillus bacteria, and/or species-specific virulent bacteriophages, and/or species-specific bacteriophages with induced virulence or their combinations with the composition containing target additives able to form a stable foam structure, is characterised by porous structure and fragility, has a relative disintegration shrinkage at least 10 %, equivalent pore diameter 10-110 mcm at particle size no more than 100 mcm and a resting angle less than 50° in the following proportions in 1.0 g of the composition: Bifidobacterium bacteria 106-1010 CFU and/or Lactobacillus bacteria 106-1010 CFU, and/or species-specific virulent bacteriophages of Appelman's lytic activity at least 10-4 with respect to test strains and bacterial isolates recovered from a human body, and/or species-specific bacteriophages of induced virulence of Appelman's lytic activity at least 10-4 with respect to test strains and bacterial isolates recovered from a human body, target additives - the rest.EFFECT: invention provides maximally achieved isotropic filling of the set volume of drug containers that provides accurate dosage of nonpathogenic microorganisms.7 cl, 9 ex

Pharmaceutical composition 'mycenorm' with antacidic action // 2442591
FIELD: medicine.SUBSTANCE: the invention relates to creation of pharmaceutical composition in the form of suspension with antacidic action. The said pharmaceutical composition contains calcium carbonate, polysaccharide sodium salt and excipients, where calcium carbonate is presented by “Micellate of calcium carbonate and magnesium”, polysaccharide sodium salt is sodium hyalurate. The composition additionally contains dimephosphon (dimethyloxobuthylphosphonilmethylate) and water. The excipients are alcohol, Nipagin and fructose. Offered pharmaceutical composition has specific pharmacological expressed effect, it showed atacidic action on the model of experimental gastritis. The composition has no expressed toxic effect with various doses and routes of experimental animals. The composition has no irritant effect, sensibilizing action was not expressed. EFFECT: the composition can be used for treatment of digestive tract pathologies and is suitable for treatment of patients additionally suffering from diabetes mellitus.2 cl, 1 tbl, 3 dwg

Controlled release pharmaceutical compositions unstable in medicinal acid medium // 2440101
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceuticals and concerns a controlled release pharmaceutical composition containing an oral dosage form of pancreatine, and an enterosoluble coating which contains a) a film-forming agent; b) a plasticiser representing mixed cetyl alcohol and triethyl citrate, and c) optionally at least one adhesion-blocking agent. The invention also concerns a method for preparing said composition and applying it for producing a pharmaceutical for digestive disorders, pancreatic exocrine insufficiency, pancreatitis, mucoviscidosis, insulin-dependent and/or insulin-independent diabetes.EFFECT: invention provides the composition having the improved release profile and storage stability.11 cl, 4 tbl, 14 ex
Gastrointestinal herbal tea // 2437673
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and can be applied for increase of therapeutic-preventive properties of medicinal vegetable mixture for treatment of gastrointestinal tract diseases. Gastrointestinal herbal tea contains leaves of mint, rhizomes of sweet flag, flowers of chamomile, root of licorice and fennel fruits in defined component ratio.EFFECT: high efficiency of herbal tea in treatment of neglected forms of disease and complications, developed before beginning of intake.
ethod of correcting intestinal microflora // 2437663
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to medicine, in particular, to field of intestine disbiosis, and can be applied for prevention or within complex therapy. Method of correcting intestinal microflora includes per oral introduction of prebiotic medication, and as prebiotic medication applied is mannose monopreparation in amount 0.01-0.02% to weight of experimental animal bode, and it is introduced in food diet of experimental animals until normal microflora is restored.EFFECT: claimed method of intestinal microflora correction makes it possible to restore intestinal microflora, excluding risk of allergic reactions development due to application of mannose monopreparation.1 tbl, 2 ex
Pills with plant extract for prevention and integrated treatment of intestinal dysbacteriosis // 2429873
FIELD: medicine.SUBSTANCE: 1 pill 0.42 g contains a plant extract 0.1 g and excipients (potato starch, gelatin and glucose (1:1:1)) in the ratio 1:3; acetone-ethanolic solution of acetylphthalyl cellulose 5 % - 12-15 layers; a 10 % hexane solution of kollidon-25 - 3-5 layers; 64 % sugar syrup - 1-2 layers.EFFECT: use of the invention provides preparation of the new home-produced herbal drug in the form of pills exhibiting antimicrobial, probiotic and anti-inflammatory action, with evident prolonged action, usable and having 2 years of shelf life.5 ex, 5 tbl
Agent for treating gastrointestinal diseases of animals // 2428194
FIELD: medicine.SUBSTANCE: invention concerns veterinary science. An agent for treating gastrointestinal diseases of animals contains preserved bile and hydrosol consisting of silver clusters and distilled water with the silver cluster concentration in hydrosol 5-100 mg/l, in the following proportions, wt %: Preserved bile - 2-4, hydrosol consisting of silver clusters and distilled water with the silver cluster concentration in hydrosol - the rest 5-100 mg/l.EFFECT: invention provides better biochemical blood values and reduced time of treatment of gastrointestinal diseases of animals.12 ex

Compositions and methods for stimulation of gastrointestinal tract locomotive function // 2420305
FIELD: medicine, pharmaceuticals.SUBSTANCE: group of inventions relates to medicine, namely to gastroenterology and can be used for stimulation of locomotive function of gastrointestinal tract. Inventions include introduction of therapeutically effective amount of peptidyl analog of ghrelin, having a sequence H-Inp-D-Bal-D-Trp-Phe-Apc-NH2 (BIM-28131), its pharmaceutically acceptable salt or in pharmaceutical composition. For this purpose various methods characterising different ways of introducing said means for various conditions, accompanied by such abnormalities are offered.EFFECT: inventions make it possible provide the most effective stimulation of locomotive activity of gastrointestinal tract in various types of abnormalities, due to selected ghrelin analog, which has by the factor of ten greater efficiency and duration of action in comparison with ghrelin.30 cl, 5 dwg, 1 tbl, 8 ex

ethod of treating scar acidosis // 2419423
FIELD: medicine.SUBSTANCE: invention relates to field of veterinary medicine. Method includes per oral application of sodium acetate in dose 275-440 g 2 times per day, preliminarily solving it in 2 l of warm water.EFFECT: method makes it possible to reduce terms of animal recovery.1 tbl, 1 ex
edication for treating intestinal dysbiosis in patients with chronic cryptogenic hepatitis // 2411955
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of pharmacy, in particular to herbal therapy, and can be used for treatment of intestinal dysbiosis in patients with chronic cryptogenic hepatitis. Medication represents herb mixture of medicinal plants, which includes rhizome of medic burnet, fruit of bird cherry, collective fruit of grey alder, herb of peppermint, fruit of fennel, roots of cultivated licorice, rhizome of common bistort, flowers of German chamomile. Additionally medication contains flowers of linden, herb of common centaury, yellow sweet clover, flax seeds, leaves of cowberries, Arctostaphylos uva-ursi, roots of heartleaf bergenia, corn stigmas, flowers of dwarf everlasting, rhizome with roots of Polemonium coeruleum L, Island moss, flowers of black elder, roots and rhizomes of garden angelica, rhizome of common tormentil, fruit of juniper, rhizome with roots of sweet flag, roots of common dandelion, eucalyptus leaves, tansy flowers, bark of common oak, herb of European oregano. Components of herb mixture are taken in definite ratio.EFFECT: intake of claimed medication enhances antimicrobial, anti-inflammatory, spasmolytic action, results in complete suppression of pathogenic flora in intestine and recovery of normal flora, as well as in reduction of toxic impact on hepatobiliary system and increase of remission period.4 ex, 2 tbl
ethod of polychemotherapeutic enteropathy prevention and treatment // 2405546
FIELD: medicine.SUBSTANCE: invention belongs to medicine, notably to oncology, and can be used in prevention and treatment of enteropathy due to intensive cytostatic polychemotherapy. To achieve this Enterosgel (Methylsiliconic acid hydrogel) is administered during whole course of polychemotherapy and after it. After cytostatic treatment during Enterosgel administration additionally nonabsorbable enteral antiseptic ersefuril is administered. normobiotics - Hylac-forte and Primadophilus™ Bifidus are administered when level of leukocytes in blood gets higher then 1000/mcl.EFFECT: method ensures prevention of necrotic processes, reparation of gastro-intestinal mucous lining and fast arresting of enteropathy due to toxic metabolites enterosorption, elimination of pathogenic and opportunistic microbes and regulation of intestinal flora balance.2 ex
edication for prevention of gastrointestinal diseases in farm animals // 2403052
FIELD: medicine, veterinary.SUBSTANCE: invention relates to field of veterinary. Medication contains cuticle of bird gizzard - 60%, iodine - 13%, starch-27%. Medication is simple to manufacture, ecologically pure.EFFECT: invention is highly efficient for prevention of gastrointestinal diseases in farm animals.
ethod of treating patients with intestinal dysbacteriosis // 2400235
FIELD: medicine.SUBSTANCE: invention relates to medicine, in particular to gastroenterology and deals with methods of treating patients with intestinal dysbacteriosis. For this purpose ursofalk in dose 1 capsule 3 times a day is introduced during one month.EFFECT: method ensures restoration of quantitative and qualitative ratio of bile acids in intestine, antiseptic effect in intestine, normalising killing activity of lymphocytes and, as a result, creates optimal conditions for restoration of microbiocoenosis.3 tbl, 4 ex
Complex preparation for treating acute gastrointestinal disturbances in calves // 2396074
FIELD: medicine.SUBSTANCE: invention refers to veterinary science, particularly to veterinary protozoology and can be used for treating gastrointestinal disturbances in newborn calves. A complex preparation for treating associative course of cryptosporidiosis, colibacteriosis, salmonellosis, rota- and coronaviral enteritis in calves, characterised by the fact that it represents a bolus consisting of agar pectin 6.0, metronidazole 1.5 and aethonium 0.5 grams introduced in a calf orally in the morning and in the evening for 3 days.EFFECT: invention provides higher clinical effectiveness.1 tbl

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof for inhibiting norepinephrine, dopamine and serotonin reuptake // 2388751
FIELD: chemistry.SUBSTANCE: invention relates to novel compounds of formula,where the carbon atom denoted * is in R- or S-configuration; X is a concentrated bicyclic carbocycle or heterocycle selected from a group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, indazolyl, indolyl, benzooxazolyl, benzothiazolyl, indenyl, indanyl, dihydrobenzocycloheptenyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, quinoxalinyl, 2H-chromenyl, imidazo[1.2-a]pyridinyl, pyrazolo[1.5-a]pyridinyl, and condensed bicyclic carbocycle or condensed bicyclic heterocycle, optionally substituted with substitutes (1 to 4) which are defined below for R14; R1 is H, C1-C6-alkyl, C3-C6-cyclalkyl, C1-C3-alkyl, substituted OR11, -NR9R10 or -CN; R2 is H, C1-C6-alkyl, or gem-dimethyl; R3 is H, -OR11, C1-C6-alkyl or halogen; R4 is H, halogen, -OR11, -CN, C1-C6-alkyl, C1-C6-alkyl, substituted -NR9R10, C3-C6-cycloalkyl, substituted -NR9R10, C(O)R12; or R4 is morpholinyl, piperidinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, isoxazolyl, pyrrolidinyl, piperazinyl, 2-oxo-2H-pyridinyl, [1.2.4]triazolo[4.3-a]pyridinyl, 3-oxo-[1.2.4]triazolo[4.3-a]pyridinyl, quinoxalinyl, which are optionally substituted with substitutes (1 to 4) which are defined below for R14; R5 is H or C1-C6-alkyl; R6 is H, C1-C6-alkyl, or -OR11; R7 is H; R8 is H, -OR9, C1-C6-alkyl, -CN; R9 is H or C1-C4-alkyl; R10 is H or C1-C4-alkyl; or R9 and R10 taken together with the nitrogen atom to which they are bonded form morpholine; R11 is H, C1-C4-alkyl; R12 is C1-C6-alkyl; R14 in each case is independently selected from a substitute selected from a group consisting of halogen, -OR11, -NR11R12, C1-C6-alkyl, which is optionally substituted with 1-3 substitutes, in each case independently selected from a group consisting of C1-C3-alkyl, aryl; or to pharmaceutically acceptable salts thereof. The invention also relates to a pharmaceutical composition, to a method of obtaining formula (I) compounds, as well as to a method of treating disorders.EFFECT: obtaining new biological active compounds having norepinephrine, dopamine and serotonin reuptake selective inhibitory activity.90 cl, 162 ex, 2 tbl

Application of simethicon for patients predisposed to constipation // 2384339
FIELD: medicine.SUBSTANCE: there are offered a set of components for preparation of a medicine used for treatment of individuals predisposed to constipation, suffering from sensation of abdominal distension within night, which includes at least, two components, representing (a) one component which contains 80 to 300 mg of simethicon in the form of a fast-release composition, (b) one component which contains 2 to 20 mg of bisacodyl in the form of a slow-release composition, and an appropriate pharmaceutical composition.EFFECT: reduced sensation of abdominal distension and meteorism within night without defecation.3 cl, 4 dwg
Preparation "diaron" for treatment of acute gastrointestinal diseases of newborn calves // 2381796
FIELD: veterinary.SUBSTANCE: preparation of treatment of gastrointestinal diseases in newborn calves, includes zeolite, tetracycline, sodium acetate and flour of dried leather bergenia rhizome (Bergenia crassifolia), at the following ratio of components, wt %: Zeolite 44.5-48.5; Sodium acetate 44.5-48.5; Flour from dried rhizome of leather bergenia (Bergenia crassifolia) 4.2-8.2; Tetracycline 1.0-2.0. Preparation is fed in dose of 35 g per head 2 times per day until recovery.EFFECT: therapeutic efficiency makes 100%.1 tbl, 4 ex
 
2551314.
Up!